Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
c-erbB-2 and episialin challenge host immune response by HLA class I expression in human non-small-cell lung cancer
Autore:
Koukourakis, MI; Giatromanolaki, A; Guddo, F; Kaklamanis, L; Vignola, M; Kakolyris, S; Turley, H; Georgoulias, V; Bonsignore, G; Gatter, KC; Harris, AL;
Indirizzi:
Univ Hosp Iraklion, Dept Radiotherapy Oncol, Crete, Greece Univ Hosp Iraklion Crete Greece Dept Radiotherapy Oncol, Crete, Greece Univ Hosp Iraklion, Canc Biol Lab, Crete, Greece Univ Hosp Iraklion Crete Greece Iraklion, Canc Biol Lab, Crete, Greece CNR, Inst Resp Physiopathol, Palermo, Italy CNR Palermo ItalyCNR, Inst Resp Physiopathol, Palermo, Italy Oxford Radcliffe Hosp, Imperial Canc Res Fund, Med Oncol Unit, Oxford, England Oxford Radcliffe Hosp Oxford England d, Med Oncol Unit, Oxford, England Oxford Radcliffe Hosp, Dept Cellular Sci, Oxford, England Oxford RadcliffeHosp Oxford England Dept Cellular Sci, Oxford, England
Titolo Testata:
JOURNAL OF IMMUNOTHERAPY
fascicolo: 1, volume: 23, anno: 2000,
pagine: 104 - 114
SICI:
1524-9557(200001)23:1<104:CAECHI>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
MHC CLASS-I; BETA-2-MICROGLOBULIN MESSENGER-RNA; MAJOR HISTOCOMPATIBILITY COMPLEX; PUTATIVE PEPTIDE TRANSPORTER; ENDOTHELIAL GROWTH-FACTOR; WILD-TYPE P53; T-CELL; PROTEIN EXPRESSION; PROGNOSTIC VALUE; GENE-EXPRESSION;
Keywords:
lung cancer; c-erbB-2; episialin; HLA class I; platelet-endothelial cell adhesion molecule 1;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
57
Recensione:
Indirizzi per estratti:
Indirizzo: Koukourakis, MI Tumour & Angiogenesis Res Grp, 18 Dimokratias Ave, Iraklion 71306, Crete, Greece Tumour & Angiogenesis Res Grp 18 Dimokratias Ave Iraklion Crete Greece 71306
Citazione:
M.I. Koukourakis et al., "c-erbB-2 and episialin challenge host immune response by HLA class I expression in human non-small-cell lung cancer", J IMMUNOTH, 23(1), 2000, pp. 104-114

Abstract

The role of major histocompatibility complex expression in cancer prognosis and pathogenesis is contradictory. The aim of the current study was to compare the expression of HLA class I molecules and of oncoproteins that may be sources of peptides presented by HLA class I antigens in non-small-cell lung cancer. For this purpose, the expression of HLA class I antigen and TAP-1 molecule (a transporter in the antigen-processing 1 transport protein) were studied with epidermal growth factor, receptor; c-erbB-2; episialin; wild type and mutant p53; bcl-2 oncoprotein expression; and angiogenic factor expression (vascular endothelial growth factor and thymidine phosphorylase). The degree of lymphocytic stromal infiltration and of platelet-endothelial cell adhesion molecule-expressing lymphocytes was also studied. A strong association of c-erbB-2 and MUC1 (episialin) expression with HLA class I expression was observed (p = 0.005 and 0.009, respectively). Intense CD31-positive lymphocytic infiltration was also more frequent in HLA class I-positive cases (p = 0.05). Although there was no association of HLA class I expression with survival, loss of the HLA class I expression in MUC1 or c-erbB-2 overexpressing cases conferred a poorer clinical outcome (p = 0.04). Both c-erbB-2 and MUC1 are well-known targets of T-cell-mediated cytotoxicity and cell-cell or cell-matrix adhesion-regulating proteins. The authors provide evidence that the sequence of cell adhesion-disrupting oncoprotein expression, HLA class I induction, and enhanced epitope presentation followed by lymphocytic response is an important pathogenetic three-step sequence of events that define, in part, the clinical outcome in non-small-cell lung cancer.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/03/20 alle ore 13:06:04